A-shares open · 港股交易中 Quotes 行情 · 28 Sep 10:35 CST
28 Sep 2026 · 10:35 CST Terminal Access 终端入口 →

Ding Lieming 丁列明

Male 男 · 63 years old · Doctorate 博士 · Seven seats at two companies · Identity confirmed by person code

Companies 任职公司

Company 公司Industry 行业Role 职务Since 起始Grade 评级
Betta Pharmaceuticals 贝达药业Chemical Pharmaceuticals 化学制药Chairman 董事长23 Aug 2013C 63
Betta Pharmaceuticals 贝达药业Chemical Pharmaceuticals 化学制药Non-independent Director 非独立董事23 Aug 2013C 63
Healthgen Biotech 禾元生物Biologics 生物制品Director 董事26 Jan 2024—
Betta Pharmaceuticals 贝达药业Chemical Pharmaceuticals 化学制药General Manager 总经理23 Aug 2013C 63
Betta Pharmaceuticals 贝达药业Chemical Pharmaceuticals 化学制药Chief Executive Officer 首席执行官23 Aug 2013C 63
Betta Pharmaceuticals 贝达药业Chemical Pharmaceuticals 化学制药Legal Representative 法定代表人23 Aug 2013C 63
Betta Pharmaceuticals 贝达药业Chemical Pharmaceuticals 化学制药Acting Board Secretary 代理董事会秘书23 Aug 2013C 63

Identity Notes 身份校验

Other Record 其他记录Verdict 判定Basis 依据
Ding Lieming 丁列明Probably the same personSame company

Biography 简历

丁列明先生:1963年12月24日出生,中国农工民主党,中国国籍,无境外居留权,1984年8月至1986年8月于浙江省嵊州市卫生防疫站工作;1989年8月至1992年6月于浙江医科大学传染病研究所任讲师;1992年6月至1996年7月于美国阿肯色大学医学院肿瘤中心任高级研究助理;1996年7月至2002年6月通过美国外国医师专业委员会的临床医学博士的考试认证,并在美国阿肯色大学医学院病理科完成了病理专业医师的全程学习和培训;2003年1月至2008年8月于浙江贝达药业有限公司任董事、总裁;2008年8月至2013年8月于浙江贝达药业有限公司任董事长,2013年8月至今任贝达药业董事长兼首席执行官、总经理;2022年6月至今,任禾元生物董事。

English Translation 英文译文 · Organisation Names in Chinese 机构名称保留中文Mr. Ding Lieming: born on December 24, 1963, member of the China Peasants' and Workers' Democratic Party, Chinese nationality, no overseas residency, worked at Zhejiang Province Shengzhou City Health and Epidemic Prevention Station from August 1984 to August 1986; from August 1989 to June 1992, worked as a lecturer at 浙江医科大学传染病研究所; from June 1992 to July 1996, worked as a senior research assistant at the Tumor Center of 美国阿肯色大学医学院; from July 1996 to June 2002, passed the clinical medicine doctor's examination and certification by the American Committee of Foreign Medical Graduates, and completed the full course of study and training in pathology at the Pathology Department of 美国阿肯色大学医学院; from January 2003 to August 2008, served as a director and president at 浙江贝达药业有限公司; from August 2008 to August 2013, served as the chairman at 浙江贝达药业有限公司, and from August 2013 to present, serves as the chairman and CEO, and general manager of Beike Biotechnology; from June 2022 to present, serves as a director of 禾元生物 (Healthgen Biotech).